Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda source : Jaguarhealth.gcs-web.com save search
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Published: 2023-08-08 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
fda drug disease health microvillus treatment application crofelemer
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published: 2023-08-01 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 1.02%
H: 0.67%
C: -2.84%
fda drug diarrhea health treatment application crofelemer
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
Published: 2023-06-28 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.53%
H: 6.69%
C: 6.28%
fda drug disease health microvillus application
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Published: 2023-05-11 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 23.61%
H: 37.08%
C: 7.87%
fda drug diarrhea approved animal
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-03-30 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -2.24%
H: 9.03%
C: -2.56%
fda veterinary drug conference diarrhea health approved animal cancer
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
Published: 2023-02-28 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.51%
H: 1.52%
C: -2.54%
fda rare designation drug disease health grants crofelemer microvillus
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Published: 2023-02-23 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 3.91%
H: 1.5%
C: -9.4%
fda drug patent health approved crofelemer
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
Published: 2023-01-30 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.18%
H: 0.36%
C: -3.53%
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -1.06%
H: 1.94%
C: 0.0%
fda health
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
Published: 2022-09-29 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 5.29%
H: 2.79%
C: -10.22%
np-300 treatment fda pharmaceuticals drug candidate diarrhea health application pathogens
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Published: 2022-08-30 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 2.69%
H: 2.5%
C: -7.67%
fda drug candidate diarrhea health application submission
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
Published: 2022-08-23 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 1.09%
H: 9.37%
C: 0.37%
fda designation drug health application crofelemer review
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
Published: 2022-02-16 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.76%
H: 1.54%
C: -3.29%
treatment fda health diarrhea crofelemer designation
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2021-09-23 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 4.8%
H: 4.58%
C: 1.67%
fda diarrhea therapy approval crofelemer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.